Literature DB >> 27056298

High vancomycin MICs within the susceptible range in Staphylococcus aureus bacteraemia isolates are associated with increased cell wall thickness and reduced intracellular killing by human phagocytes.

Rocío Falcón1, Alba Martínez2, Eliseo Albert1, Silvia Madrid1, Rosa Oltra3, Estela Giménez1, Mario Soriano4, Víctor Vinuesa1, Daniel Gozalbo2, María Luisa Gil5, David Navarro6.   

Abstract

Vancomycin minimum inhibitory concentrations (MICs) at the upper end of the susceptible range for Staphylococcus aureus have been associated with poor clinical outcomes of bloodstream infections. We tested the hypothesis that high vancomycin MICs in S. aureus bacteraemia isolates are associated with increased cell wall thickness and suboptimal bacterial internalisation or lysis by human phagocytes. In total, 95 isolates were evaluated. Original vancomycin MICs were determined by Etest. The susceptibility of S. aureus isolates to killing by phagocytes was assessed in a human whole blood assay. Internalisation of bacterial cells by phagocytes was investigated by flow cytometry. Cell wall thickness was evaluated by transmission electron microscopy. Genotypic analysis of S. aureus isolates was performed using a DNA microarray system. Vancomycin MICs were significantly higher (P=0.006) in isolates that were killed suboptimally (killing index <60%) compared with those killed efficiently (killing index >70%) and tended to correlate inversely (P=0.08) with the killing indices. Isolates in both killing groups were internalised by human neutrophils and monocytes with comparable efficiency. The cell wall was significantly thicker (P=0.03) in isolates in the low killing group. No genotypic differences were found between the isolates in both killing groups. In summary, high vancomycin MICs in S. aureus bacteraemia isolates were associated with increased cell wall thickness and reduced intracellular killing by phagocytes.
Copyright © 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Cell wall thickness; Human phagocytes; Intracellular killing; Minimum inhibitory concentration (MIC); Staphylococcus aureus; Vancomycin

Mesh:

Substances:

Year:  2016        PMID: 27056298     DOI: 10.1016/j.ijantimicag.2016.01.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Association of Vancomycin MIC and Molecular Characteristics with Clinical Outcomes in Methicillin-Susceptible Staphylococcus aureus Acute Hematogenous Osteoarticular Infections in Children.

Authors:  Eric Y Kok; Jesus G Vallejo; Lauren M Sommer; Louie Rosas; Sheldon L Kaplan; Kristina G Hulten; J Chase McNeil
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Reproducible measurement of vancomycin MICs within the susceptible range in Staphylococcus aureus by a broth microdilution method with a "quasi-continuum" gradient of antibiotic concentrations.

Authors:  R Falcón; E M Mateo; A Talaya; E Giménez; V Vinuesa; M Á Clari; D Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-25       Impact factor: 3.267

3.  Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.

Authors:  Rocío Falcón; Eva Mateo; Rosa Oltra; Estela Giménez; Eliseo Albert; Ignacio Torres; David Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-06       Impact factor: 3.267

4.  Cells released from S. epidermidis biofilms present increased antibiotic tolerance to multiple antibiotics.

Authors:  Vânia Gaio; Nuno Cerca
Journal:  PeerJ       Date:  2019-05-15       Impact factor: 2.984

5.  Effect of the vancomycin minimum inhibitory concentration on clinical outcomes in patients with methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.

Authors:  Changcheng Shi; Jian Ye; Renjie Xu; Weizhong Jin; Shuang Xu; Fei Teng; Nengming Lin
Journal:  BMJ Open       Date:  2021-01-15       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.